- The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomide - - In a pivotal PPMS study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback